SMAD3 and neoplasm: SMAD3, a key mediator of the TGF-β signaling pathway [6], demonstrates significant upregulation in advanced-stage LUAD compared with early-stage disease, correlating with increased tumor aggressiveness, invasive capacity, and poor patient outcomes [7].